Related Experiment Video
Updated: Sep 15, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
SERUM LncRNA SNHG16: A Biomarker for Diagnosing Childhood Obesity and Predicting Its Progression to Metabolic
Junjie Hu1, Zufen Zheng2, Dakang Liang1
1Department of General Pediatrics, Sihui People's Hospital, Sihui, 526200, People's Republic of China.
Purpose:
Obesity is a major risk factor for metabolic syndrome (MS) in children. This study explores the expression and clinical significance of long non-coding RNA SNHG16 (SNHG16) in childhood obesity and its complications with MS (obesity-MS).
Patients And Methods:
Healthy controls and obese children (categorized as those with simple obesity or obesity-MS) were enrolled. Serum SNHG16 and miR-27a-3p levels were quantified by RT-qPCR. ROC curves evaluated SNHG16's diagnostic value for obesity. Logistic regression analysis identified potential risk factors for the development of obesity-MS. DLR assay and RIP assay confirmed the interaction between SNHG16 and miR-27a-3p. Bioinformatics was used to predict downstream genes of miR-27a-3p and, then GO and KEGG enrichment analysis identified the functions and signaling pathways of these genes.
Results:
Serum SNHG16 levels were distinctly upregulated in obese children, especially those with obesity-MS. In contrast, miR-27a-3p expression showed the opposite trend. Additionally, SNHG16 was positively correlated with BMI in obese children. Serum SNHG16 exhibited 81.18% sensitivity and 76.47% specificity in distinguishing controls from obese individuals. Furthermore, serum SNHG16, BMI, HOMA-IR, and TG are potential risk factors for MS in obese children. Mechanistically, SNHG16 directly targets miR-27a-3p, and miR-27a-3p targets 65 genes primarily enriched in insulin response and the MAPK, Ras, and mTOR signaling pathways.
Conclusion:
Elevated serum SNHG16 levels may serve as diagnostic biomarkers for obese children and predict obesity-MS. SNHG16 may also contribute to the progression of obesity and MS by targeting miR-27a-3p.
